The Library
Adjuvant therapy in pancreatic cancer : historical and current perspectives
Tools
Tools
Tools
Neoptolemos, J. P., Cunningham, D., Friess, H., Bassi, C., Stocken, D. D., Tait, D. M., Dunn, Janet A., Dervenis, C., Lacaine, F., Hickey, H., Raraty, M. G. T., Ghaneh, P. and Büchler, M. W. (2003) Adjuvant therapy in pancreatic cancer : historical and current perspectives. Annals of Oncology, 14 (5). pp. 675-692. doi:10.1093/annonc/mdg207
Research output not available from this repository, contact author.
Official URL: https://doi.org/10.1093/annonc/mdg207
Abstract
The results from pancreatic ductal adenocarcinoma appear to be improving with increased resection rates and reduced postoperative mortality reported by specialist pancreatic cancer teams. Developments with medical oncological treatments have been difficult, however, due to the fundamentally aggressive biological nature of pancreatic cancer and its resistance to chemotherapy coupled with a relative dearth of randomised controlled trials. The European Study Group for Pancreatic Cancer (ESPAC)-1 trial recruited nearly 600 patients and is the largest trial in pancreatic cancer. The results demonstrated that the current best adjuvant treatment is chemotherapy using bolus 5-fluorouracil with folinic acid. The median survival of patients randomly assigned to chemoradiotherapy was 15.5 months and is comparable with many other studies, but the median survival in the chemotherapy arm was 19.7 months and is as good or superior to multimodality treatments including intra-operative radiotherapy, adjuvant chemoradiotherapy and neo-adjuvant therapies. The use of adjuvant 5-fluorouracil with folinic acid may be supplanted by gemcitabine but requires confirmation by ongoing clinical trials, notably ESPAC-3, which plans to recruit 990 patients from Europe, Canada and Australasia. Major trials such as ESPAC-1 and ESPAC-3 have set new standards for the development of adjuvant treatment and it is now clear that such treatment in this field has the potential to significantly improve both patient survival and quality of life after curative resection.
| Item Type: | Journal Item | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
||||
| Journal or Publication Title: | Annals of Oncology | ||||
| Publisher: | Oxford University Press | ||||
| ISSN: | 0923-7534 | ||||
| Official Date: | 1 May 2003 | ||||
| Dates: |
|
||||
| Volume: | 14 | ||||
| Number: | 5 | ||||
| Page Range: | pp. 675-692 | ||||
| DOI: | 10.1093/annonc/mdg207 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Open Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
